An interventional study of resuscitative endovascular occlusion of the aorta (REBOA) and Advanced Cardiac Life Support (ACLS) in Cardiac Arrest, sponsored by Insel Gruppe AG, University Hospital Bern. Recruiting at 1 site in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-21.
Sponsored by Insel Gruppe AG, University Hospital Bern · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies in Heart Arrest with a site in Switzerland — 5 open to participants now, 6 under way, none of them phase 3. Heart Arrest · Switzerland.
Among the 29 studies in Heart Arrest with a site in Switzerland, this one is the 8th largest by planned enrollment of the 17 interventional ones that give a count, is the only one that started in 2026, is one of 16 with no phase, and was the 28th registered.
927 studies on the registry are indexed under Heart Arrest; 227 are open to participants now.
Browse Heart Arrest studies →5 of the 29 studies in Heart Arrest with a site in Switzerland are open now. Recruiting first, the newest first:
Hochgebirgsklinik Davos · Sites in Switzerland
Ages 18+
University Hospital, Ghent · Sites in Switzerland, Austria, Belgium and 5 more countries
Ages 18+
Felix Brinkmann · Sites in Switzerland
Ages 18+
Pediatric Clinical Research Platform · Sites in Switzerland
Ages 18–65 · Healthy volunteers
A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →
Of the 157 Heart Arrest studies recruiting now, 109 (69%) set no upper age limit and 28 (18%) stop at 75 or younger; 30 take children under 18; 18 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 98 is close to the median of 100 across 519 interventional studies indexed under Heart Arrest.
Median enrollment 54 across the 17 interventional studies, 360 across the 12 observational. Of the 20 that completed or were terminated, 2 (10%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 29 have an industry lead sponsor. The 10 most frequent:
Insel Gruppe AG, University Hospital Bern is the lead sponsor of 744 studies on the registry; 182 are open to participants now.
Insel Gruppe AG, University Hospital Bern has 5 studies filed under Heart Arrest — fewer than ten, so there is no comparison to draw.
3 of the studies in Heart Arrest with a site in Switzerland that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07579390Helsinki University Central HospitalEffects of Sedation, TEmperature and Pressure After Cardiac Arrest and REsuscitation on Major Adverse Kidney Events (STEPCARE-MAKE) | 2026-12 |
| NCT07026773University Hospital, GhentValidity of ICU Clinician's Appraisal of Proportionality in CPR | 2026-12-30 |
| NCT07323667Felix BrinkmannA Study on the Impact of a New Canton-Wide First Responder System in Zug, Switzerland, on Survival After Adult Cardiac Arrest-Examining Early Life-Saving Organized Help, Fast Defibrillation, and Improved Outcomes for Out of Hospital Cardiac Arrest | 2027-06-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 29 studies in Heart Arrest with a site in Switzerland, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will test if a sustained Return of Spontaneous Circulation (ROSC) in patients with cardiac arrest is more frequent when patients receive advanced cardiac life support (ACLS) alone or when they receive ACLS plus a balloon occlusion of the thoracic aorta.
Patients with in-hospital cardiac arrest (IHCA) outside the operating room, the coronary angiography suite and the intensive care unit (ICU) will be attended to by the hospitals resuscitation team and provided with advanced cardiac life support (ACLS) as per usual practice.
A research team will be deployed simultaneously and, when patients meet inclusion criteria, will randomize patients to ACLS alone or to ACLS plus balloon occlusion of the descending thoracic aorta by means of a resuscitative endovascular occlusion of the aorta (REBOA) catheter.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Advanced Cardiac Life Support (ACLS) as per the hospitals standard protocol, including advanced interventions such as extended cardio-pulmonary resuscitation (eCPR).
Other: Advanced Cardiac Life Support (ACLS)
Advanced Cardiac Life Support (ACLS) as per the hospitals standard protocol, including advanced interventions such as eCPR plus resuscitative balloon occlusion of the descending thoracic aorta (REBOA).
Device: resuscitative endovascular occlusion of the aorta (REBOA) · Other: Advanced Cardiac Life Support (ACLS)
Insertion of a balloon catheter through the common femoral artery, retrograde advancement of the catheter into the descending thoracic aorta, ballon occlusion of the aorta
Advanced Cardiac Life Support (ACLS) as per American Heart Association (AHA) or European Resuscitation Council (ERC) standards
Sustained ROSC
Any return of spontaneous circulation lasting longer then 20 minutes
Time frame: Up to 1 hour after study inclusion
Survival to hospital discharge
dead or alive
Time frame: at hospital discharge, up to 90 days after study inclusion
Survival to six month
dead or alive
Time frame: 6 month after study inclusion
neurologic outcome at the time of 30 days
measured by means of modified ranking scale
Time frame: Day 30 after study inclusion
neurologic outcome at the time of six month
measured by means of modified ranking scale
Time frame: 6 month after study inclusion
ICU-free days before hospital discharge
Time frame: at hospital discharge, up to 90 days after study inclusion
ICU-free days at 30 days
Time frame: 30 days after study inclusion
non-invasive cerebral oxygenation during resuscitation
Exploratory, measured in %
Time frame: Continuously assessed during ongoing resuscitation, up to 1 hour after study inclusion
cause of death
exploratory, written description
Time frame: at six month
Troponin T trajectory
exploratory
Time frame: at inclusion, 30 minutes after inclusion and once up to day 3
Neuron-Specific Enolase (NSE) trajectory
exploratory
Time frame: at inclusion, 30 minutes after inclusion and once up to day 3
Plan to share: Yes — All IBD (including data dictionaries) will be shared upon reasonable request with researcher eligible health data under Swiss legislation. Eligibility will be determined by Cantonal Ethics Committee of Bern. This determination will require submission of a research plan to the ethics committee. Data will be provided as electronic files in STATA file format as exported from the RedCap study database. The trials study protocol is available on the trial website at http://cpreboa.org. The statistical analysis protocol will become available on the trial website an in the Zenodo registry before inclusion of the last patient into the trial.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Analytic code
Time frame: After publication of the trial results. Data will remain available for five years.
Access criteria: Upon reasonable request to researcher eligible to work with coded individual biological, non-genetic health data under Swiss legislation - see above.
Data sharing details ↗ · cpreboa.org
Started Apr 2026 (actual). Primary completion is estimated for Dec 2030, 56 months after the start.
Of 205 non-industry interventional studies with no phase under Heart Arrest, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 47. This study's planned 56 months is above that.
Counting every sponsor, half of 219 studies reached it within 28 months; a quarter within 10 and three quarters within 48.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Insel Gruppe AG, University Hospital Bern →